Approvals· August 29, 2026 · 15 min read
Lisraya's DM Label: Boxed-Warning 30 mg Tablet, Table 3 Split, Unapproved 15 mg
By Ran Chen#FDA Approval#JAK Inhibitor#Dermatology
Topic
Dermatology
Atopic dermatitis, psoriasis, biologic competition, payer restrictions, and dermatology access workflows.
Specialty· August 15, 2026 · 26 min read
Hidradenitis Suppurativa Access: Adalimumab Spread, Biologics, & Oral JAKs
By Ran Chen#Dermatology#Biosimilars#Interchangeability
Approvals· July 3, 2026 · 17 min read
Icotyde (icotrokinra) FDA approval and oral IL-23 psoriasis access
By Ran Chen#FDA Approval#Dermatology#Immunology
Pipeline· June 8, 2026 · 10 min read
Veterinary JAK inhibitors Apoquel to Numelvi: FDA pathway compared
Pricing & Access· May 27, 2026 · 10 min read
Cosentyx access guide: secukinumab coverage and benefit routing
By Ran Chen#Immunology#Prior Authorization#Payer Policy
Pricing & Access· May 27, 2026 · 9 min read
Taltz prior authorization guide for ixekizumab access
By Ran Chen#Immunology#Prior Authorization#Payer Policy
Pricing & Access· May 24, 2026 · 12 min read
JAK inhibitor access landscape: Rinvoq, Xeljanz, Olumiant, Leqselvi, and Cibinqo in 2026
By Ran Chen#JAK Inhibitor#Immunology#Coverage Access